Cystic Fibrosis Foundation distributed the following clinical trial updates in December. Click the trial title to get more details.
Status: Enrolling
Description: This trial will look at the safety and effectiveness of the drug MS1819 as a pancreatic enzyme replacement therapy.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 30% or greater
Number of Visits: 10
Length of Participation: 11 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03746483
OPTIMIZE: Phase 3 study of tobramycin solution for inhalation with and without azithromycin
Status: Completed with results
Description: This study evaluated the effect of treatment with tobramycin inhalation solution (TIS) with and without azithromycin in people with CF who had their first isolation of Pseudomonas aeruginosa (Pa) from a respiratory culture (or their first culture after being negative for Pa for at least 2 years).
Age: 6 Months to 18 Years
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 8
Length of Participation: 18 months
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02054156